The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring
NCT ID: NCT02437760
Last Updated: 2015-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2015-02-28
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
NCT07012759
A Prognosis and Predicting Genetic Study of Lung Cancer
NCT03234179
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
NCT00897143
Prognostic Factors on Malignant Pleural Effusion
NCT03276715
Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood
NCT05587114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum and pleural effusion CA-125 level
serum and pleural effusion(if exist) CA-125 are collected:
* at time of diagnosis
* every 3 month during treatment
* stop at the progression or after 12 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy or breast milk feeding
* TB pleuritis and peritonitis
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
E-DA Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
E-DA hospital
Kaohsiung City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMRP49103N
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.